Related coverage linked through entity extraction aliases.
Aug 21, 2026
IceCure Medical's ProSense cryoablation system gains IRB approval for the ChoICE post-marketing study in low-risk breast cancer, with patient enrollment expected soon. Additionally, Thomas Hospital in Alabama becomes the first facility in the state to install ProSense, with procedures starting this month.
Mar 12, 2026
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
Feb 26, 2026
Early trial of Rezatapopt shows 20% response rate in advanced cancers with p53 mutations, while researchers identify AMD3100 as potential solution to enable immunotherapy in rare liver cancer.
Feb 13, 2026
Researchers find that AMD3100, an existing FDA-approved drug, can reverse T-cell exclusion in fibrolamellar carcinoma, potentially allowing immunotherapy to fight the rare and fatal liver cancer that primarily affects children and young adults.
Feb 13, 2026
Study finds FDA-approved drug AMD3100 can mobilize immune T cells to attack fibrolamellar carcinoma, a rare liver cancer affecting children and young adults that has resisted immunotherapy treatment.
